文献速递胸部肿瘤头颈与中枢神经肿瘤

脑放疗联合卡瑞利珠单抗及铂类双药化疗治疗初治晚期伴脑转移非小细胞肺癌(C-Brain):多中心单臂2期试验

Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2025-01-01

这项在中国九家三级医院开展的多中心单臂2期试验纳入65例初治、无EGFR/ALK/ROS1可靶向驱动基因突变且伴脑转移的晚期非小细胞肺癌患者,给予脑放疗联合卡瑞利珠单抗及铂类双药化疗;中位随访14.1个月时6个月无进展生存率为71.7%(95%CI 58.9-81.1),3-4级治疗相关不良事件以血细胞减少为主,无治疗相关死亡,作者认为该方案显示出有前景的疗效且毒性可控,需随机对照试验确认。

要点

  • 中位随访14.1个月时6个月无进展生存率为71.7%(95%CI 58.9-81.1)。
  • 3-4级治疗相关不良事件最常见为中性粒细胞计数降低,14例(22%)/65例。
  • 3级神经系统毒性3例(5%)/65例,放射性坏死3例(5%)/65例均为1-2级,无治疗相关死亡。

核心结论

  • 脑放疗联合卡瑞利珠单抗及铂类双药化疗显示出有前景的疗效和可控的毒性,可能成为伴脑转移非小细胞肺癌患者的潜在治疗选择。
  • 作者指出需要随机对照试验来确认这些发现。

研究设计与样本

  • 多中心、单臂、2期试验,在中国九家三级医院开展。
  • 纳入标准为年龄18岁及以上、新诊断的非小细胞肺癌脑转移、无可靶向驱动基因突变(EGFR、ALK或ROS1)、ECOG体能状态评分0或1。
  • 2020年5月6日至2023年1月30日共评估67例患者,2例因脑病灶小于5 mm被排除,65例入组并接受治疗。
  • 中位年龄66岁(IQR 62-70);60例(92%)/65例为男性,5例(8%)/65例为女性;65例均为汉族;50例(77%)/65例为非鳞状非小细胞肺癌,46例(71%)/65例有症状。
  • 治疗为立体定向放射外科或全脑放疗联合卡瑞利珠单抗(200 mg静脉注射,每3周一次)及研究者选择的铂类双药化疗:非鳞状NSCLC用培美曲塞500 mg/m2联合铂类(卡铂曲线下面积5或顺铂75 mg/m2),鳞状NSCLC用白蛋白结合型紫杉醇260 mg/m2联合铂类(卡铂AUC 5或顺铂75 mg/m2),共4至6个周期;疾病控制后,鳞状NSCLC用卡瑞利珠单抗单药维持(200 mg静脉注射,每3周一次),非鳞状NSCLC用卡瑞利珠单抗联合培美曲塞(500 mg/m2,每3周一次)维持。

主要发现

  • 中位随访14.1个月(IQR 9.0-20.3;数据截止2023年12月13日)时,6个月无进展生存率为71.7%(95%CI 58.9-81.1)。
  • 最常见的3-4级治疗相关不良事件为中性粒细胞计数降低(14例[22%]/65例)、白细胞计数降低(10例[15%]/65例)、血小板计数降低(10例[15%]/65例)和淋巴细胞计数降低(9例[14%]/65例)。
  • 3级神经系统毒性反应发生于3例(5%)/65例患者;放射性坏死发生于3例(5%)/65例患者,均为1级或2级。
  • 无治疗相关死亡。

关键数值与推荐

  • 6个月无进展生存率为71.7%(95%CI 58.9-81.1),中位随访14.1个月(IQR 9.0-20.3)。
  • 卡瑞利珠单抗剂量为200 mg静脉注射、每3周一次;培美曲塞500 mg/m2;卡铂AUC 5;顺铂75 mg/m2;白蛋白结合型紫杉醇260 mg/m2;铂类双药化疗共4至6个周期。
  • 维持治疗:鳞状NSCLC为卡瑞利珠单抗单药200 mg静脉注射每3周一次,非鳞状NSCLC为卡瑞利珠单抗联合培美曲塞500 mg/m2每3周一次。
  • 3-4级中性粒细胞计数降低14例(22%)/65例,白细胞计数降低10例(15%)/65例,血小板计数降低10例(15%)/65例,淋巴细胞计数降低9例(14%)/65例。

临床怎么用

  • 作者认为该方案显示出有前景的疗效和可控的毒性,可能成为伴脑转移非小细胞肺癌患者的潜在治疗选择。
  • 作者指出需要随机对照试验来确认这些发现。

局限性

  • 作者指出需要随机对照试验来确认这些发现。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brain metastases are a common complication in patients with non-small-cell lung cancer (NSCLC) lacking actionable driver mutations, with limited treatment options and poor prognosis. We aimed to investigate the efficacy and safety of brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy in patients with newly diagnosed advanced NSCLC and brain metastases. METHODS: This multicentre, single-arm, phase 2 trial was done across nine tertiary hospitals in China. Eligible patients were aged 18 years or older, had newly diagnosed brain metastases from NSCLC with no actionable driver mutations (EGFR, ALK, or ROS1), and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible patients were treated with stereotactic radiosurgery or whole-brain radiotherapy combined with camrelizumab (200 mg intravenously once every 3 weeks) and investigator-selected platinum-doublet chemotherapy (pemetrexed 500 mg/m2 plus platinum [carboplatin, area under curve (AUC) of 5, or cis-platinum 75 mg/m2] for non-squamous NSCLC, and nab-paclitaxel 260 mg/m2 plus platinum [carboplatin AUC 5, or cis-platinum 75 mg/m2] for squamous NSCLC) for four to six cycles. Patients with controlled disease then received maintenance treatment with camrelizumab alone (200 mg intravenously once every 3 weeks; for squamous NSCLC) or camrelizumab plus pemetrexed (500 mg/m2 every 3 weeks; for non-squamous NSCLC). The primary endpoint was 6-month progression-free survival rate in the full analysis set, which included all patients who received at least one dose of study treatment regardless of whether they had measurable brain lesions per RECIST 1.1. The trial was registered with ClinicalTrials.gov, NCT04291092, and is ongoing. FINDINGS: Between May 6, 2020, and Jan 30, 2023, 67 patients were assessed for eligibility. Two patients were excluded (brain lesions less than 5 mm) and 65 patients were enrolled and treated. Median age was 66 years (IQR 62-70). 60 (92%) of 65 patients were male and five (8%) were female. All 65 patients were Han Chinese. 50 (77%) of 65 patients had non-squamous NSCLC and 46 (71%) were symptomatic. The 6-month progression-free survival rate was 71·7% (95% CI 58·9-81·1) during the median follow-up of 14·1 months (IQR 9·0-20·3; data cutoff Dec 13, 2023). The most common grade 3-4 treatment-related adverse events were decreased neutrophil count (14 [22%] of 65 patients), decreased white blood cell count (ten [15%]), decreased platelet count (ten [15%]), and decreased lymphocyte count (nine [14%]). Neurological toxic effects of grade 3 occurred in three (5%) of 65 patients. Radiation necrosis occurred in three (5%) of 65 patients; all were grade 1 or 2. There were no treatment-related deaths. INTERPRETATION: Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy shows promising efficacy and manageable toxicity and could be a potential treatment option for patients with brain metastases from NSCLC. Randomised controlled trials will be required to confirm these findings. FUNDING: Beijing Xisike Clinical Oncology Research Foundation and Jiangsu Hengrui Pharmaceuticals. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Xu Y, Chen K, Xu Y, et al. Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025. PMID: 39756446. doi:10.1016/S1470-2045(24)00643-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。